Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Vertex Pharmaceuticals Inc (VRTX)  
$437.49 8.90 (2.08%) as of 4:30 Wed 5/15


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 260,040,000
Market Cap: 113.76(B)
Last Volume: 1,059,413 Avg Vol: 1,615,310
52 Week Range: $323.57 - $446.08
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Drug Manufacturers - Other

Member Indexes:
    S&P COMPOSITE 1500     NASDAQ BIOTECHNOLOGY
    NASDAQ COMPOSITE     NASDAQ-100
    S&P 400 MIDCAP     NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  543
Guru Rank Value     : 3
Guru Occurances    : 1

 

            6 Months   1 Year   2 Year  
 
Company Profile   Vertex Pharmaceuticals is a biotechnology company. Co. has clinical and research programs to develop treatment of cystic fibrosis. In addition, Co. has a pipeline of investigational therapies in other diseases where it is utilizing insight into causal human biology, including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, type 1 diabetes, pain, alpha-1 antitrypsin deficiency, and muscular dystrophies. Co.'s marketed CF medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor in combination with ivacaftor), ORKAMBI (lumacaftor in combination with ivacaftor) and KALYDECO (ivacaftor).

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 45,457 125,099 237,443 597,852
Total Sell Value $19,193,323 $51,578,069 $92,174,963 $199,924,371
Total People Sold 8 11 14 18
Total Sell Transactions 19 38 60 128
End Date 2024-02-15 2023-11-14 2023-05-16 2022-05-16

   
Records found: 3266
  Page 19 of 131  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Leiden Jeffrey M Executive Chairman   •       •      –    2021-02-10 4 D $214.16 $2,988,389 D/D (13,954) 63,646     -
   Altshuler David EVP, Global Research and CSO   •       –      –    2021-02-10 4 D $214.16 $636,912 D/D (2,974) 58,381     -
   Wagner Charles F Jr EVP & Chief Financial Officer   •       –      –    2021-02-10 4 D $214.16 $506,488 D/D (2,365) 35,773     -
   Arbuckle Stuart A EVP, Chief Commercial Officer   •       –      –    2021-02-10 4 D $214.16 $664,110 D/D (3,101) 66,856     -
   Parini Michael EVP, Chief Adm, Leg & BD Off   •       –      –    2021-02-10 4 D $214.16 $548,892 D/D (2,563) 54,664     -
   Sanna Bastiano EVP, Cell & Genetic Therapies   •       –      –    2021-02-10 4 D $214.16 $287,831 D/D (1,344) 40,550     -
   Silva Paul M SVP & Chief Accounting Officer   •       –      –    2021-02-10 4 D $214.16 $139,418 D/D (651) 25,361     -
   Kewalramani Reshma CEO & President   •       •      –    2021-02-10 4 D $214.16 $634,342 D/D (2,962) 68,621     -
   Sachdev Amit EVP, Chief Patient Officer   •       –      –    2021-02-10 4 D $214.16 $518,481 D/D (2,421) 68,002     -
   Tatsis Ourania EVP, Chief Reg. & Quality Off.   •       –      –    2021-02-10 4 D $214.16 $263,417 D/D (1,230) 34,468     -
   Bozic Carmen EVP and CMO   •       –      –    2021-02-10 4 D $214.16 $506,917 D/D (2,367) 33,575     -
   Parini Michael EVP, Chief Adm, Leg & BD Off   •       –      –    2021-02-05 4 AS $215.00 $414,950 D/D (1,930) 57,227 -13%     
   Parini Michael EVP, Chief Adm, Leg & BD Off   •       –      –    2021-02-05 4 OE $86.52 $166,984 D/D 1,930 59,157     -
   Sanna Bastiano EVP, Cell & Genetic TherapiesO   •       –      –    2021-02-03 3 IO $0.00 $0 D/D 0 21,175 -10%     
   Arbuckle Stuart A EVP, Chief Commercial Officer   •       –      –    2021-02-03 4 AS $211.22 $332,146 D/D (1,554) 69,957 -10%     
   Arbuckle Stuart A EVP, Chief Commercial Officer   •       –      –    2021-02-03 4 OE $86.52 $134,452 D/D 1,554 71,511     -
   Arbuckle Stuart A EVP, Chief Commercial Officer   •       –      –    2021-02-03 4 A $0.00 $0 D/D 34,778 69,957     -
   Wagner Charles F Jr EVP & Chief Financial Officer   •       –      –    2021-02-03 4 A $0.00 $0 D/D 21,951 38,138     -
   Sachdev Amit EVP, Chief Patient Officer   •       –      –    2021-02-03 4 A $0.00 $0 D/D 32,077 70,423     -
   Silva Paul M SVP & Chief Accounting Officer   •       –      –    2021-02-03 4 A $0.00 $0 D/D 11,080 26,012     -
   Altshuler David EVP, Global Research and CSO   •       –      –    2021-02-03 4 A $0.00 $0 D/D 32,453 61,355     -
   Sanna Bastiano EVP, Cell & Genetic Therapies   •       –      –    2021-02-03 4 A $0.00 $0 D/D 20,719 41,894     -
   Leiden Jeffrey M Executive Chairman   •       •      –    2021-02-03 4 D $215.03 $1,849,043 D/D (8,599) 77,600     -
   Leiden Jeffrey M Executive Chairman   •       •      –    2021-02-03 4 A $0.00 $0 D/D 83,888 86,199     -
   Parini Michael EVP, Chief Adm, Leg & BD Off   •       –      –    2021-02-03 4 AS $215.52 $86,624 D/D (400) 57,227 -10%     
  3266 Records found
  Previous  10  11  12  13  14  15  16  17  18  19  Next   
  Page 19 of 131
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us